Pharming B.V.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Pharming B.V.
Live alerts from global media, monitored by Business Radar
2025-02-07 (iex.nl)
Pharming declares bid on Abliva unconditionally
Pharming Technologies, a subsidiary of Pharming Group, explains the bid for the Swedish ABLiva AB unconditionally, now that around 87.8 percent of the ABLiva shares have been registered under Hat Bod. Pharming announced this late on Friday.
Read more
2025-02-07 (iex.nl)
Pharming declares bid on Abliva unconditionally
Pharming Technologies, a subsidiary of Pharming Group, explains the bid for the Swedish ABLiva AB unconditionally, now that around 87.8 percent of the ABLiva shares have been registered under Hat Bod. Pharming announced this late on Friday.
Read more
2025-01-18 (manda.be)
Biotech on the move: signs of recovery, major funding rounds, maturing of the European sector and trends in focus areas -
Six top experts on developments in the biotech sector. Biotech on the move: signs of recovery, major funding rounds, maturing of the European sector and trends in focus areas MandA
Read more
2025-01-18 (manda.be)
Biotech on the move: signs of recovery, major funding rounds, maturing of the European sector and trends in focus areas -
Six top experts on developments in the biotech sector. Biotech on the move: signs of recovery, major funding rounds, maturing of the European sector and trends in focus areas MandA
Read more
2025-01-17 (iex.nl)
Outgoing CEO Sijmen de Vries: 'Pharming is certainly not ready yet in terms of takeovers'
Pharming recently announced the acquisition of Abliva: a good time for an interview with outgoing CEO Sijmen de Vries.
Read more
2025-01-17 (iex.nl)
Outgoing CEO Sijmen de Vries: 'Pharming is certainly not ready yet in terms of takeovers'
Pharming recently announced the acquisition of Abliva: a good time for an interview with outgoing CEO Sijmen de Vries.
Read more
2025-01-16 (beleggersbelangen.nl)
What should we make of the recent Pharming takeover? - BeleggersBelangen.nl
On December 15, Pharming announced a public cash offer for Swedish Abliva. The offer of SEK0.45 per share corresponds to one
Read more
2025-01-16 (beleggersbelangen.nl)
What should we make of the recent Pharming takeover? - BeleggersBelangen.nl
On December 15, Pharming announced a public cash offer for Swedish Abliva. The offer of SEK0.45 per share corresponds to one
Read more
2025-01-16 (iex.nl)
Fundlogic sells almost its entire stake in Pharming
Fundlogic SAS has almost completely sold its interest in Pharming Group. This emerged on Thursday from a notification in the context of the Financial Supervision Act, dated January 14, 2025.
Read more
2025-01-16 (iex.nl)
Fundlogic sells almost its entire stake in Pharming
Fundlogic SAS has almost completely sold its interest in Pharming Group. This emerged on Thursday from a notification in the context of the Financial Supervision Act, dated January 14, 2025.
Read more
2025-01-16 (iex.nl)
Fundlogic sells almost its entire stake in Pharming
Fundlogic SAS has almost completely sold its interest in Pharming Group. This emerged on Thursday from a notification in the context of the Financial Supervision Act, dated January 14, 2025.
Read more
2025-01-16 (mena.nl)
Biotech on the move: signs of recovery, larger financing rounds, maturing of the European sector and trends in focus areas -
The biotech sector has faced a number of challenges over the past few years, both for the private and public markets. This editorial special reflects on the developments. The past few years have been challenging years for the biotech sector, both in Europe and the United States. There was a lot of capital available until 2021 […]
Read more